68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma

Study acronym: NYHCC
StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 7 more changesShow less
    • Primary endpoints: details revised at 1 of 2 entries
    • Primary and study completion moved earlier from Jun 1, 2027 to Apr 1, 2027
    • Start date changed from estimate of Jun 1, 2026 to Jun 11, 2026
    • Interventions: 68Ga-NYM207 PET/CT (Diagnostic Test) to 68Ga-NYM207 PET/CT (Diagnostic Test)
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 4 of 4 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is a prospective, single-center, single-arm, phase I/II study designed to evaluate (1) the safety, tolerability, and imaging characteristics of 68Ga-NYM207 (Phase A), and (2) the diagnostic performance of 68Ga-NYM207 in detecting hepatocellular carcinoma (HCC) (Phase B). This study will provide critical insights into the performance of 68Ga-NYM207 PET/CT as a non-invasive imaging tool for the detection of HCC.
Trial Details
NCT Number NCT07590336
Lead Sponsor Peking Union Medical College Hospital
Conditions
(from sponsor)		 Hepatocellular Carcinoma (HCC)
Related terms Carcinoma, Hepatocellular
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov